Inventor · disambiguated record
Romain Ollier
Also filed as: OLLIER ROMAIN · OLLIER ROMAIN CHRISTIAN
6 granted patents·14 pending applications·58 citations·filing 2013–2023
80Inventor score
Top patents by PatentIndex Score
20 records- 0196US9493563B2Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Nov 15, 2016·47 cites·3 claims
- 0294US11891454B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2020·Granted Feb 6, 2024·3 cites·15 claims
- 0389US11773166B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2018·Granted Oct 3, 2023·5 cites·12 claims
- 0488US11851502B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2018·Granted Dec 26, 2023·3 cites·13 claims
- 0576US2022213227A1T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2022·Application pending·0 cites
- 0672US12006367B2CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their productionIchnos Sciences SA·Filed 2022·Granted Jun 11, 2024·0 cites·9 claims
- 0769US2020102403A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 0861US2017145115A1Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 0960US2025320284A1Novel Molecules for Therapy and DiagnosisAC IMMUNE SA·Filed 2022·Application pending·0 cites
- 1059US2020010568A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 1158US2018112011A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2015·Application pending·0 cites
- 1256US2025145695A1Humanized Anti-TDP-43 Binding Molecules and Uses ThereofAC IMMUNE SA·Filed 2023·Application pending·0 cites
- 1354US2015183885A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 1452US2015239991A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2013·Application pending·0 cites
- 1549US2013344064A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2013·Application pending·0 cites
- 1649US2016319027A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 1746US2023322908A1Humanized Anti-TDP-43 Binding Molecules and Uses ThereofAC IMMUNE SA·Filed 2021·Application pending·0 cites
- 1844US2017218087A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 1944US2025340623A1Novel Molecules for Therapy and DiagnosisAC IMMUNE SA·Filed 2020·Application pending·0 cites
- 2038US10640564B2Antibodies that bind to CCR6 and their usesIchnos Sciences SA·Filed 2015·Granted May 5, 2020·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →